Predicting cognitive worsening using subjective reports of dyads and biological biomarkers in pre‐clinical stages: Preliminary results from the CompAS cohort study

Abstract Background The utility of cognitive complaints and biological biomarkers as a factor risk of dementia among cognitively unimpaired individuals is not yet clear (Nosheny et al., 2022). Our aim was to study the joint contribution of subjective reports and some plasma biomarkers to predict cognitive worsening from preclinical stages. Method One‐hundred older adults identified as CU and SCD from the CompAS study, and their corresponding informants, were followed with an average time of 59.86 months (range=47‐77; SD=7.36). After an extensive neuropsychological assessment, they were diagnosed by applying consensus criteria. The Memory Failure of Everyday (MFE), a 28‐item questionnaire (Sunderland et al., 1984), was administered at baseline to participants and informants for assessing memory complaints and plasma biomarkers p ‐tau217, Aβ42 and Aβ40 were obtained from participants (see Table 1). Logistic regression analysis was used to predict stability and worsening towards MCI or dementia at last follow‐up, using total MFE scores (self‐report and informant) and plasma tau‐217 and Aβ42/Aβ40 ratio as predictors. Results Regression model showed significant predictive associations between worsening towards MCI or dementia and higher participant MFE total‐score and Plasma p ‐tau levels, (see Table 2). The informant MFE total‐score was close to achieve significance ( p = .050) and Aβ42/40 ratio failed in predicting progression. The model fitting parameters showed acceptable fits ( χ 2 = 14.267, p = .014; Nalgelkerke R 2 = .203; Hosmer & Lemeshow test= 5.713; p = .679). Classification values were: Sensibility=21.1, Specificity=98.8, and Overall percentage=84.0. Conclusions Results showed that higher MFE score from participants and levels of plasma p ‐tau217 were associated to increased risk of cognitive worsening in pre‐clinical stages. These results should be considered with caution given that the model classified better the stable than the worsening participants.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70856_104822
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predicting cognitive worsening using subjective reports of dyads and biological biomarkers in pre‐clinical stages: Preliminary results from the CompAS cohort study

Cristina Lojo‐Seoane, Onésimo Juncos‐Rabadán, Fátima Fernández‐Feijoo, Lucía Pérez‐Blanco et al.
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
article

Predicting cognitive worsening using subjective reports of dyads and biological biomarkers in pre‐clinical stages: Preliminary results from the CompAS cohort study

Cristina Lojo‐Seoane, Onésimo Juncos‐Rabadán, Fátima Fernández‐Feijoo, Lucía Pérez‐Blanco, Ana Nieto‐Vieites, Ana Rodríguez‐Pérez, Alba Felpete, David Facal, Arturo X. Pereiro Rozas
article en

Abstract

Abstract Background The utility of cognitive complaints and biological biomarkers as a factor risk of dementia among cognitively unimpaired individuals is not yet clear (Nosheny et al., 2022). Our aim was to study the joint contribution of subjective reports and some plasma biomarkers to predict cognitive worsening from preclinical stages. Method One‐hundred older adults identified as CU and SCD from the CompAS study, and their corresponding informants, were followed with an average time of 59.86 months (range=47‐77; SD=7.36). After an extensive neuropsychological assessment, they were diagnosed by applying consensus criteria. The Memory Failure of Everyday (MFE), a 28‐item questionnaire (Sunderland et al., 1984), was administered at baseline to participants and informants for assessing memory complaints and plasma biomarkers p ‐tau217, Aβ42 and Aβ40 were obtained from participants (see Table 1). Logistic regression analysis was used to predict stability and worsening towards MCI or dementia at last follow‐up, using total MFE scores (self‐report and informant) and plasma tau‐217 and Aβ42/Aβ40 ratio as predictors. Results Regression model showed significant predictive associations between worsening towards MCI or dementia and higher participant MFE total‐score and Plasma p ‐tau levels, (see Table 2). The informant MFE total‐score was close to achieve significance ( p = .050) and Aβ42/40 ratio failed in predicting progression. The model fitting parameters showed acceptable fits ( χ 2 = 14.267, p = .014; Nalgelkerke R 2 = .203; Hosmer & Lemeshow test= 5.713; p = .679). Classification values were: Sensibility=21.1, Specificity=98.8, and Overall percentage=84.0. Conclusions Results showed that higher MFE score from participants and levels of plasma p ‐tau217 were associated to increased risk of cognitive worsening in pre‐clinical stages. These results should be considered with caution given that the model classified better the stable than the worsening participants.

Alzheimer s & DementiaVol. 21(S2)
Universidade de Santiago de Compostela (ES), Biomedical Research Networking Center on Neurodegenerative Diseases (ES), Center for Research in Molecular Medicine and Chronic Diseases (ES), Centro de Investigación Biomédica en Red (ES), Instituto de Investigación Sanitaria de Santiago (ES)
Openalex Percentile: Top 29%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.